Plaque psoriasis is a common disease that causes red, scaly, raised lesions on the skin, most commonly on the elbows, knees, scalp, and back. Psoriasis affects about 2% of the population and significantly decreases health-related quality of life. It is a chronic inflammatory condition associated with systemic diseases.

For questions, contact

View the Key Stakeholders List.

Interventions of interest:

  • Anti TNF agents: Adalimumab (Humira®, AbbVie), etanercept (Enbrel®, Amgen, Inc.), infliximab (Remicade®, Janssen)
  • Anti IL-17A agents: Secukinumab (Cosentyx®, Novartis), ixekizumab (Taltz®, Eli Lilly and Co.), brodalumab (SiliqTM, Valeant Pharmaceuticals and AstraZeneca)
  • Anti IL-12/23 agent: Ustekinumab (Stelara®, Janssen)
  • Anti PDE4 agent: Apremilast (Otezla®, Celgene)

Final Documents

Below you will find the final documents from the assessment review process: